Preferred Label : GLPG0634;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3242562/jyseleca
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
filgotinib
filgotinib
filgotinib
administration, oral
female
arthritis, rheumatoid
Janus Kinase Inhibitors
Janus Kinase Inhibitors
evaluation of the transparency committee
GLPG0634
GLPG0634
pyridines
triazoles
pyridines
triazoles

---
https://www.ema.europa.eu/en/medicines/human/EPAR/jyseleca
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
filgotinib
filgotinib
filgotinib
adult
arthritis, rheumatoid
administration, oral
drug therapy, combination
methotrexate
Janus Kinase Inhibitors
Janus Kinase Inhibitors
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
GLPG0634
GLPG0634
pyridines
triazoles
pyridines
triazoles

---
Nous contacter.
16/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.